These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 30855644

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A, Schaeffer EK, Reilly CW.
    J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
    [Abstract] [Full Text] [Related]

  • 3. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM, Rauch F, Jacob P, McCormick A, McMillan HJ, Matzinger MA, Ward LM.
    Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
    [Abstract] [Full Text] [Related]

  • 4. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, DesClouds P, Cram D, Page M, Konji VN, Lentle B, Ward LM.
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [Abstract] [Full Text] [Related]

  • 5. Fracture risk and impact in boys with Duchenne muscular dystrophy: A retrospective cohort study.
    Liaw J, Billich N, Carroll K, Adams J, Ryan MM, Yiu EM, Zacharin M, Simm P, Davidson ZE.
    Muscle Nerve; 2023 Jun; 67(6):489-496. PubMed ID: 36478256
    [Abstract] [Full Text] [Related]

  • 6. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L, Zhou H, Xu H, Sun X, Chen X, Fan P, Cai X, Wang Q.
    Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
    [Abstract] [Full Text] [Related]

  • 7. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Smit K, Walker S, Hartigan C, Khan N, Konji VN, MacLeay L, Page M, Sykes E, Robinson ME, Alos N, Cummings EA, Ho J, Sbrocchi AM, Stein R, Saleh D, Craven BC, Dang UJ, Siminoski K, Rauch F, Ward LM.
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [Abstract] [Full Text] [Related]

  • 8. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT, Joseph S, Capaldi N, Brown S, Di Marco M, Dunne J, Horrocks I, Shepherd S, Ahmed SF, Wong SC.
    Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
    [Abstract] [Full Text] [Related]

  • 9. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ, Adams JE, Padidela R, Shaw NJ, Högler W, Roper H, Hughes I, Daniel A, Mughal MZ.
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [Abstract] [Full Text] [Related]

  • 10. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
    Mayo AL, Craven BC, McAdam LC, Biggar WD.
    Neuromuscul Disord; 2012 Dec; 22(12):1040-5. PubMed ID: 22824639
    [Abstract] [Full Text] [Related]

  • 11. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Speed C, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Griggs RC, FOR-DMD Investigators of the Muscle Study Group, Straub V, van Ruiten H, Childs AM, Ciafaloni E, Shieh PB, Spinty S, Maggi L, Baranello G, Butterfield RJ, Horrocks IA, Roper H, Alhaswani Z, Flanigan KM, Kuntz NL, Manzur A, Darras BT, Kang PB, Morrison L, Krzesniak-Swinarska M, Mah JK, Mongini TE, Ricci F, von der Hagen M, Finkel RS, O'Reardon K, Wicklund M, Kumar A, McDonald CM, Han JJ, Joyce N, Henricson EK, Schara-Schmidt U, Gangfuss A, Wilichowski E, Barohn RJ, Statland JM, Campbell C, Vita G, Vita GL, Howard JF, Hughes I, McMillan HJ, Pegoraro E, Bello L, Burnette WB, Thangarajh M, Chang T.
    JAMA; 2022 Apr 19; 327(15):1456-1468. PubMed ID: 35381069
    [Abstract] [Full Text] [Related]

  • 12. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD, Politano L, Harris VA, Passamano L, Vajsar J, Alman B, Palladino A, Comi LI, Nigro G.
    Neuromuscul Disord; 2004 Sep 19; 14(8-9):476-82. PubMed ID: 15336688
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ, NorthStar UK Network and CINRG DNHS Investigators.
    JAMA Netw Open; 2022 Jan 04; 5(1):e2144178. PubMed ID: 35076703
    [Abstract] [Full Text] [Related]

  • 14. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C, Wong BL, Hornung L, Khoury JC, Miller L, Bange J, Rybalsky I, Rutter MM.
    Neuromuscul Disord; 2016 Nov 04; 26(11):760-767. PubMed ID: 27614576
    [Abstract] [Full Text] [Related]

  • 15. Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
    Phung K, McAdam L, Ma J, McMillan HJ, Jackowski S, Scharke M, Matzinger MA, Shenouda N, Koujok K, Jaremko JL, Wilson N, Walker S, Hartigan C, Khan N, Page M, Robinson ME, Saleh DS, Smit K, Rauch F, Siminoski K, Ward LM.
    J Clin Endocrinol Metab; 2024 Jan 18; 109(2):536-548. PubMed ID: 37610420
    [Abstract] [Full Text] [Related]

  • 16. Fractures and bone health monitoring in boys with Duchenne muscular dystrophy managed within the Scottish Muscle Network.
    Joseph S, Wang C, Di Marco M, Horrocks I, Abu-Arafeh I, Baxter A, Cordeiro N, McLellan L, McWilliam K, Naismith K, Stephen E, Ahmed SF, Wong SC.
    Neuromuscul Disord; 2019 Jan 18; 29(1):59-66. PubMed ID: 30473133
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A, Liguori S, Paoletta M, Gimigliano F, Iolascon G.
    Adv Ther; 2022 Jul 18; 39(7):3308-3315. PubMed ID: 35614293
    [Abstract] [Full Text] [Related]

  • 18. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B, Matthews DJ, Clayton GH, Carry T.
    Am J Phys Med Rehabil; 2005 Nov 18; 84(11):843-50. PubMed ID: 16244521
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
    Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H, Hor KN, Cripe LH, Wong BL.
    Neuromuscul Disord; 2012 Dec 18; 22(12):1046-56. PubMed ID: 22967789
    [Abstract] [Full Text] [Related]

  • 20. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY, Kuntzer T, Pike M, Swan A.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD003725. PubMed ID: 18254031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.